MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a phase Ib trial that evaluates the safety and tolerability of MK-2206 given in
combination with exemestane +/- goserelin in pre- and post-menopausal patients with hormone
receptor-positive metastatic breast cancer.